Clinical significance of nuclear factor kappaB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
10.3904/kjim.2014.29.6.785
- Author:
Ho Cheol SHIN
1
;
Jongwon SEO
;
Byung Woog KANG
;
Joon Ho MOON
;
Yee Soo CHAE
;
Soo Jung LEE
;
Yoo Jin LEE
;
Seoae HAN
;
Sang Kyung SEO
;
Jong Gwang KIM
;
Sang Kyun SOHN
;
Tae In PARK
Author Information
1. Department of Hematology and Oncology, Kyungpook National University Hospital, Daegu, Korea. bwkang@knu.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Lymphoma;
NF-kappa B;
CXCR4
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Antibodies, Monoclonal, Murine-Derived/administration & dosage;
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use;
Chi-Square Distribution;
Cyclophosphamide/administration & dosage;
Disease Progression;
Disease-Free Survival;
Doxorubicin/administration & dosage;
Female;
Humans;
Immunohistochemistry;
Kaplan-Meier Estimate;
Lymphoma, Large B-Cell, Diffuse/chemistry/*drug therapy/mortality/pathology;
Male;
Middle Aged;
Multivariate Analysis;
NF-kappa B/*analysis;
Neoplasm Staging;
Predictive Value of Tests;
Prednisone/administration & dosage;
Proportional Hazards Models;
Receptors, CXCR4/*analysis;
Retrospective Studies;
Risk Factors;
Time Factors;
Treatment Outcome;
Tumor Markers, Biological/*analysis;
Vincristine/administration & dosage;
Young Adult
- From:The Korean Journal of Internal Medicine
2014;29(6):785-792
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: This study investigated the expression of nuclear factor kappaB (NF-kappaB) and the chemokine receptor (CXCR4) in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based therapy. METHODS: Seventy patients with DLBCL and treated with rituximab-CHOP (R-CHOP) were included, and immunohistochemistry was performed to determine the expression of NF-kappaB (IkappaB kinase alpha, p50, and p100/p52) and CXCR4. To classify DLBCL cases as germinal center B-cell-like (GCB) and non-GCB, additional immunohistochemical expression of CD10, bcl-6, or MUM1 was used in this study. The expression was divided into two groups according to the intensity score (negative, 0 or 1+; positive, 2+ or 3+). RESULTS: The median age of the patients was 66 years (range, 17 to 87), and 58.6% were male. Twenty-seven patients (38.6%) had stage III or IV disease at diagnosis. Twenty-three patients (32.9%) were categorized as high or high-intermediate risk according to their International Prognostic Indexs (IPIs). The overall incidence of bone marrow involvement was 5.7%. Rates of positive NF-kappaB and CXCR4 expression were 84.2% and 88.6%, respectively. High NF-kappaB expression was associated with CXCR4 expression (p = 0.002), and 56 patients (80.0%) showed coexpression. However, the expression of NF-kappaB or CXCR4 was not associated with overall survival and EFS. On multivariate analysis that included age, gender, performance status, stage, and the IPI, no significant association between the grade of NF-kappaB or CXCR4 expression and survival was observed. CONCLUSIONS: The current study suggests that the tissue expression of NF-kappaB and CXCR4 may not be an independent prognostic marker in DLBCL patients treated with R-CHOP.
